Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemrametostat (GSK3326595) in MDS, CMML, and AML
NCT03614728Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pemrametostat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by GSK. Started Oct 2018; status: terminated.
02
Drugs
pemrametostat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03614728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614728.